Immunisation Update

April 2005

Stephen Pellissier
Immunisation Program

Today's session

- Vaccine recommendations
  - Pneumococcal
  - Poliomyelitis
  - New combination vaccines
  - Varicella
  - Meningococcal C

Provides clear guidelines about vaccination practice

http:/immunise.health.gov.au/handbook.htm



Pneumococcal Incidence in children

- I year olds (117 per 100,000)
- Infants (80 per 100,000)

Declines thereafter:

- 2 year olds (55 per 100,000)
- 3 year olds (26 per 100,000)
- 4 year olds (19 per 100,000)

NCIRS Newsletter July 2004

Childhood Pneumococcal vaccine

- 1 January 2005 eligibility
  - All children born on or after 1 Jan. 2003
  - All infants at 2, 4 & 6 months of age
  - Children under 5 years with certain medical risk factors (boosters required)
- Prevenar vaccine
  - 7 vPCV
  - ~80% of invasive isolates in children
  - >95% protective efficacy against IPD due to serotypes in the vaccine

Catch up schedule

- **3 - 6 months**
  - 3 doses, 2 months apart
- **7 - 17 months**
  - 2 doses, 2 months apart
- **>= 18 months**
  - 1 dose

Childhood Pneumococcal medical risk factors

Children under 5 years

- Down's syndrome
- Premature infants with chronic lung disease
- Infants born less than 28 wks gestation
- Cystic Fibrosis
- Insulin-dependent diabetes
- Intracranial shunts & cochlear implants

Childhood Pneumococcal medical risk factors cont.

Vaccine doses required:

- Prevenar vaccine for primary doses
- Booster dose of Prevenar at 12 months of age
- Pneumovax 23 booster at 4 to 5 years of age

Adult Pneumococcal Vaccine Program

- Pneumovax 23 now funded by the Australian Government
- Recommended for:
  - All aged 65 years & over
  - A&TSI people aged 50 years & over
  - All aged 5 years & over with chronic illnesses or immunocompromised
  - Tobacco smokers

Adult Pneumococcal Vaccine Program cont.

- Pneumovax 23 vaccine boosters recommended for:
  - Non-indigenous adults 65 years & over: a single revaccination 5 years later
  - Non-indigenous adults less than 65 years with risk factors: a single revaccination at 65 years of age or 10 years after the first dose whichever comes later
  - A&TSI adults 50 years and over: a single revaccination 5 years later
  - A&TSI adults 15 to 49 years with risk factors: 2 boosters, 5 years later then either 10 years later or at age 50 whichever is later

OPV versus IPV

OPV

- Cost $3
- Side effects
  - Excreted in the faeces for up to 6 weeks
  - Vaccine Associated Paralytic Poliomyelitis (VAPP) 1 in 2.5 million first doses

IPV

-Cost $35

-Side effects

New IPV combinations
Infanrix-hexa

- Infanrix-hexa
  - DTPa-hepB-Hib-IPV
  - Fewer injections at 2 and 4 months of age

BUT

- Hib component is PRP-T (not PRP-OMP)
  - not suitable for Indigenous children
  - requires a 3 dose primary course
  - Hib booster at 12 months

Infanrix-hexa

AND

- Use at 2, 4 and 6 months means 4 doses of hep B vaccine by 12 months
  - Comvax at 12 months results in 5 doses of hep B vaccine
  - ATAGI have indicated this is acceptable

Other IPV combinations

- Infanrix-penta
  - DTPa-hepB-IPV
  - requires separate Hib vaccine
  - not useful where Comvax (Hib-hepB) used
- Infanrix-IPV
  - DTPa-IPV
  - useful with Comvax

IPV ?combination

- Infanrix-hexa
  - fewer injections at 2 and 4 months
  - $105
- Infanrix-penta
  - $80
- Infanrix-IPV
  - $70
- IPV - $40

Varicella

- For most children chicken pox will be the worse illness of their childhood

- 'Severe' chicken pox
  - Pneumonia
  - Encephalitis
  - Secondary bacterial infection



Varicella is preventable

- Varicella vaccine
  reduces the chance of shingles

- Children 12 months and over receive a single dose

- Any adolescent or adult without a history of chicken pox and negative serology receive 2 doses.

National Meningococcal C vaccine program

- Target group are:
  - All children aged 1 to 19 years in 2003 are now eligible for free meningococcal C vaccine
  - Mop up program to mid 2006

Meningococcal C program coverage – DHS Victoria

Primary school	>90%
High school Yrs 7 - 9	80%
High school Yrs 10 - 12	75%

1 Jan 2000 to 15 April 2005, notifications of meningococcal disease

Year of notification	Serogroup					Total
	Group B	Group C	Group W135	Group Y	Unknown	
2000	52	72	4	5	29	162
2001	47	56	1	1	58	163
2002	56	88	6	4	54	208
2003	55	47	2	2	23	129
2004	55	13	1	3	8	80
2005	10	1	2	0	1	14

Immunisation coverage 31 December 2004- ACIR

	Victoria	Australia
12-<15 mths	**90.8%**	90.7%
24-<27 mths	**92.2%**	91.7%
72-<75 mths	**85.7%**	83.3%

Immunisation contacts

- ACIR enquiries 1800 653 809

- DHS Immunisation Program
  1300 882 008

www.health.vic.gov.au/immunisation